This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-15 and is reviewed periodically as new material appears.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
In Western societies, the contexts for depictions of the human body include information, art and pornography. Information includes both science and education, such as anatomical drawings. Any ambiguous image not easily fitting into one of these categories may be misinterpreted, leading to disputes. The most contentious disputes are between fine art and erotic images, which define the legal distinction of which images are permitted or prohibited.
According to the Chinese chronicles of the Jin dynasty (265-316 CE), there were already a thousand Buddhist stupas and temples in Kucha by the 3rd century CE. The earliest painted caves at Kizil are thought to be Cave of the Hippocampi (Cave 118) and Treasure Caves C and B (Caves 83 and 84 respectively). Cave 118, possibly the earliest of the three, is located deep inside the central valley. Cave 83 and 84 are located at the entrance of the same valley. These caves have simple architectural structures, together with paintings in a clear style, reflecting Indian influences. Noble or wealthy Tocharian donors from Kucha, wearing tunics, sometimes appear kneeling at the side of devotional paintings.
Some sources state that it does not exist, or at least has never been observed, while other sources assert or imply its existence. Despite this controversy, many properties of diatomic astatine have been predicted; for example, its bond length would be 300±10 pm, dissociation energy <50 kJ/mol, and heat of vaporization (∆vapH) 54.39 kJ/mol. Many values have been predicted for the melting and boiling points of astatine, but only for At2.
=== STC2 === STC2 was discovered from the human DNA database. In human STC2 is produced by STC2 gene which is located in the long arm of human chromosome 5 (position q35.1). It is very different from STC1 and show only 34% similarity. STC2 mRNA is found in pancreas, kidney, spleen, and skeletal muscles.
For Psylocke’s new look, which I collaborated on with Chris Claremont, she appears on the cover in armor. That was my first take on the character, which I had to get done for the cover before I had finished the interior look, and I don’t think Chris had signed off on yet. He didn’t like that direction as much -- he wanted something slinkier, more like Elektra -- that you eventually see inside that issue. But that discussion led us to modify the story a little. When you first see her, she’s in that armor, and through a psychic conflict, you see it smashed off of her body to unveil the new costume that Chris wanted. A 1993 story by Fabian Nicieza would retroactively establish that Braddock's changed appearance was the product of a body swap between Braddock and the assassin Kwannon. In the Claremont-written X-Treme X-Men #2 (2001), the character dies, her comic book death lasting until 2005's Uncanny X-Men #455. During the 2018 "Hunt for Wolverine" storyline, the psychic vampire Sapphire Styx absorbs Braddock's soul, leaving her body dead. After destroying Styx from the inside with assistance from a fragment of Wolverine's soul, Braddock reconstitutes her original body with Styx's remaining soul power. During the Dawn of X, Braddock subsequently took up her brother Brian's former title of Captain Britain, forming a new iteration of Excalibur with Apocalypse, Gambit, Rogue, Jubilee, and Rictor, to protect the Kingdom of Avalon.
Sources: en.wikipedia.org
=== Human === People can be exposed to crude oil through various ways, such as skin contact, inhalation, and ingestion, and those can be happened simultaneously. Especially, residents of oil abundant areas are at the risk of exposure to water which has been contaminated by oil. They consume this polluted water by drinking, cooking and cleaning. The exhibition of crude oil to human can affect mentality and occur symptoms such as anxiety, depression, headache, and sore eyes and throat. Additionally, it causes various troubles with regard to brain, endocrine and DNA. There is a reported case that shows how fatal effects can occur to human due to crude oil. A child, exposed to BLCO to cure febrile convulsion, had symptoms of “sequel of shock, acute renal failure, mechanical intestinal obstruction, extensive epidermolysis, conjunctivitis, mucositis, oesophagitis and chemical pneumonitis"
From 13 to 15 May 2026, the president of the United States Donald Trump made a state visit to China. This visit was Trump's second state visit to China, and the first to occur during his second presidency. Trump's first state visit to China occurred in November 2017. This trip was also the first by a U.S. president since Trump's visit in 2017. During the visit, Trump was received by CCP general secretary Xi Jinping at the Great Hall of the People, where the two leaders held talks. Xi announced the two sides had agreed to establish a Constructive Strategic and Stable Relationship. Following the talks, Xi and Trump visited the Temple of Heaven, the second US president to visit the Temple while in office after President Gerald Ford in 1975. Later, Xi hosted Trump for a dinner banquet at the Golden Room of the Great Hall of the People. Trump invited Xi for a state visit to the United States on 24 September 2026. At the second day of the visit on 15 May, Trump visited the Chinese leadership compound Zhongnanhai. The visit was the first of the four summits between Xi and Trump in 2026. It was reciprocated by a state visit by Xi Jinping to the United States in September 2026. Additionally, Trump is scheduled travel to China for APEC 2026 in November while Xi is scheduled to visit the United States for 2026 G20 Miami summit in December.
Cyclotides are a family of cysteine-rich peptides characterized by six conserved cysteines that form three disulfide bonds within the cyclic structure forming the characteristic cyclic cystine knot (CCK) that confers these peptides their characteristic 3D structure and it is believed to be greatly responsible for the stability and properties of the cyclotides.
Such treatment reduces the risk of death. Additionally, they may benefit from cognitive behavioral therapy, other forms of support from mental health professionals such as individual or group therapy, twelve-step programs, and other peer support programs. The medication naltrexone may also be useful to prevent relapse. Naloxone is useful for treating an opioid overdose and giving those at risk naloxone to take home is beneficial. This disorder is much more prevalent than first realized. In 2020, the CDC estimated that nearly 3 million people in the U.S. were living with OUD and more than 65,000 people died by opioid overdose, of whom more than 15,000 overdosed on heroin. In 2022, the U.S. reported 81,806 deaths caused by opioid-related overdoses. Canada reported 32,632 opioid-related deaths between January 2016 and June 2022.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.